Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of BIBX 245 CL in Healthy Subjects
NCT02264197Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 1998
- Primary completion
- Jun 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BIBX-245 in hyperlipidemia (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analyte in plasma, Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity and 4 more. Started May 1998; status: completed.
02
Drugs
BIBX-245
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT02264197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264197.